<DOC>
	<DOCNO>NCT01130064</DOCNO>
	<brief_summary>The purpose study investigate efficacy 24 week intravenous treatment QAX576 patient persistent asthma adequately control inhaled corticosteroid long act beta2-agonists .</brief_summary>
	<brief_title>Efficacy QAX576 Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Male female patient Female patient must surgically sterilize postmenopausal Male patient must use two form contraception Body mass index must 18 39 kg/m2 Diagnosis asthma least one year , adequately control inhaled corticosteroid long act beta2 agonist Smoking history &gt; 10 packyears Patients diagnosis chronic obstructive pulmonary disease ( COPD ) Patients experience severe asthma attack/exacerbation require systemic corticosteroid increase maintenance dos , within 6 week screen Patients respiratory tract infection within 6 week prior screen History schistosomiasis , within 6 month screen , travel country endemic schistosomiasis within 6 month complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Asthma</keyword>
	<keyword>QAX576</keyword>
</DOC>